NEW YORK (AP) — Shares of Pharmasset Inc. climbed Tuesday after the company said it is starting late-stage clinical trials of an experimental hepatitis C drug.
THE SPARK: The Princeton, N.J., company, is planning a 12-week study that treats hepatitis C with a combination of its experimental drug called PSI-7977 and ribavirin. Both drugs are given orally, and the regimen does not include the intravenous drug interferon. The company said it will enroll 500 patients with all types of hepatitis C. Some will get PSI-7977 and ribavirin, and the others will get the standard treatment for hepatitis C, a combination of ribavirin pills and intravenous interferon.
Pharmasset expects to start enrolling patients before the end of 2011. The company said it will start two other late-stage trials in 2012 and hopes to file for marketing approval of PSI-7977 in the U.S. and European Union in the second half of 2013.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
